Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

PRINCETON, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported operational highlights and financial results for the fiscal quarter ended December 31, 2008.

Financial Results

Revenues were $0.5 million during each of the quarters ended December 31, 2008 and December 31, 2007 and reflect amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities was $15.3 million for the quarter ended December 31, 2008 as compared to $17.1 million for the quarter ended December 31, 2007. Pharmasset held $51.8 million in cash and cash equivalents and short term investments at the end of the fiscal first quarter.

Total costs and expenses for the quarter ended December 31, 2008 were $18.1 million as compared to $13.2 million for the same period in 2007. The increased operating expenses for the quarter ended December 31, 2008 were primarily the result of an increase in phase 3 registration clinical trial expenses for clevudine for the treatment of chronic hepatitis B (HBV) infection, as well as increased preclinical development expenses for our second generation HCV product candidate, PSI-7851.

Pharmasset reported a net loss attributable to common stockholders of $18.3 million, or $0.78 per share for the quarter ended December 31, 2008, as compared to a net loss attributable to common stockholders of $12.2 million, or $0.57 per share for the quarter ended December 31, 2007.

Recent Highlights:

-- In November 2008, Roche initiated the INFORM-1 trial, a potentially ground-breaking study to investigate the activity of a com
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...UNNYVALE, Calif., Nov. 5 ... executives will be speaking at the following inve...pate via webcast. , , Credit Suiss... Thursday, 12 November, 2009 at 10 a.m. Mountai...Program, London, England, Tuesday,...
(Date:11/5/2009)...USTIN, Texas, Nov. 5 SpineSmith Pa...eo, Inc. to co-develop a unique scaffold that mimi...owing evaluation of several commercial products by... the company believes the GenOsteo scaffold repres...creates a unique and ideal environment for the del...
(Date:11/5/2009)... Brooke Sanders brings a new loo...CA (PRWEB) November 5, 2009 -- Professional Reprog...rographics company is pleased to present Brooke Sa...their graphics/PR specialist. The addition of Broo...ent growth within Professional Reprographics., , ,...
(Date:11/4/2009)...ETERSBURG, Va., Nov. 4 ...d today that the company plans to introduce the Ci...sidiary, Rock Creek Pharmaceuticals, for worldwide...v Health, Inc . (Nasdaq: VTIV). inVentiv Health ...ions for every stage of the product lifecycle, in ...
Breaking Biology Technology:Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4
...-FirstCall/ - Helix BioPharma Corp.,(TSX: HBP / Fr...of Kenneth,D. Hatch, M.D., as a new medical adviso...to Helix on its clinical-stage compound, Topical,I...s caused by HPV. Dr.,Hatch is a professor of obste... "Dr. Hatch complements our medical advisory team...
...lan, LOWELL, Mass., Oct. 11 More than half of,Ma...ir own companies, but,are concerned about the curr...ew statewide poll of 500 CEOs released today by th...roject (MEAAP) -- a joint project of,UMass Boston ...rveyed said their own businesses were,growing comp...
... Technologies today,launched a new corporate websi...audiences: Life Scientists, Flow Cytometrists, and...al tool for cell analysis, Guava,Technologies is d...chnology,as practical as possible for all life sci...edication is obvious from the audience-centric,org...
Other Biology Technology:Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor 2Survey Sees Mass. CEOs as Bullish on Own Businesses 2New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians 2
(Date:11/4/2009)...PRNewswire-FirstCall/ -- BIO-key International, In...based biometric identification software is showcas...BB TXPO conference being held at the New Orleans C...will provide hands-on product demonstrations of it...oth #424. Also, at 5 PM on Monday, October 26, Pet...
(Date:11/3/2009)... 2009 -- The world,s greatest wines are the resul...n input, and something called the "terroir" -- a t...climate. , Experts will discuss terroir with a...sday, Nov. 4 in Pittsburgh. "Terroir: Winegrapes ...s at the 2009 Annual Meetings of the American Soci...
(Date:11/3/2009)...e women are as much as 28 percent less likely to b...cording to research that earned a Michigan State U...ings by Barbara Luke, a researcher in the MSU Coll...Gynecology and Reproductive Biology, focused on da...ive technology. , Luke,s findings, which also ca...
Breaking Biology News(10 mins):BIO-key(R) International Exhibiting at AABB TXPO 2Great wines come from great soils 2MSU researcher: Obesity significantly cuts odds of successful pregnancy 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent Safe Topical Anti Androgens 13080 1Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent Safe Topical Anti Androgens 13080 2Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent Safe Topical Anti Androgens 13080 3EcoloBlue is a New source of Water and a New Green Industry 52068 1EcoloBlue is a New source of Water and a New Green Industry 52068 2Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20 20 as a Secret Weapon for Treating for Burn Scars 52063 1Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20 20 as a Secret Weapon for Treating for Burn Scars 52063 2Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20 20 as a Secret Weapon for Treating for Burn Scars 52063 3Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20 20 as a Secret Weapon for Treating for Burn Scars 52063 4
...ave been jangled by a baby,s howl or who have been...s, nature has evolved sensory systems to be exquis... neurobiology is how neurons tune the strength of ...h inputs. , Neuronal circuitry consists of a web o...sts of neurotransmitters at targets on receiving n...
...dical Center is enrolling volunteers in a study to...rst such vaccine against the virus. The Vanderbilt...e new vaccine in nearly 100 individuals 65 years o...l study led by the National Institute of Allergy a...avian flu vaccine trial, conducted at various othe...
...tiny rainforest outpost of Australia have driven t...ss, according to scientists from the University of...y, and the Queensland Parks and Wildlife Service. ...ritz, professor of integrative biology at UC Berke...gy. "To find a recently evolved species like this ...
Other Biology News:Grasshopper love songs give insight into sensory tuning 2Volunteers sought for avian flu vaccine study 2Picky female frogs drive evolution of new species in less than 8,000 years 2Picky female frogs drive evolution of new species in less than 8,000 years 3Picky female frogs drive evolution of new species in less than 8,000 years 4
Rat IgG2b Clone: A95-1, Allophycocyanin Conjugated/Tagged from BD Biosciences Pharmingen
Mouse BLC / BCA 1 from Antigenix America Inc.
Goat Anti-Bag-1 (K-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
... the 3, 3', 4, and 4' positions. It is intended fo...on of Prostaglandin E2 (PGE2) by GC- or LC-mass sp...ase products of arachidonic acid and one of the mo...y influences inflammation, fertility and parturiti...
Biology Products: